Regulatory hub

UK regulatory framework for peptides. Live tracker.

Five regulators set the rules for peptides, collagen and GLP-1 medicines in the UK. We track what they are saying, in plain English, and link to the primary sources.

Last reviewed 2026-07-19. Editorial commentary, not legal advice.

AI-friendly summary · UK regulatory framework

As of July 2026, MHRA regulates licensed UK medicines, including all GLP-1 weight-management medications, which are Prescription Only. That covers the first GLP-1 tablet licensed for weight management, approved on 11 June 2026, which is also prescription-only and cannot be advertised to the public. WADA prohibits most research peptides under S0 or S2 for tested athletes. FDA decisions on Category 1 Bulk Drug Substances are widely cited but not binding in the UK. EMA opinions are typically mirrored by MHRA. ASA enforces the CAP Code on health and weight-loss claims, including the POM advertising ban, which MHRA, ASA and GPhC restated jointly on 18 June 2026.

The five jurisdictions we track

Each regulator below has a separate remit. We summarise what each one covers, link to our existing deep-dive where it exists, and flag where a deep-dive is still in build.

MHRA

Medicines and Healthcare products Regulatory Agency

UK regulator for licensed medicines and medical devices. Classifies medicines as POM, P or GSL. Acts on unlicensed medicinal product supply.

MHRA medicines classification

WADA

World Anti-Doping Agency

International anti-doping authority. Publishes the annually-updated Prohibited List. UK Anti-Doping (UKAD) enforces it on tested athletes.

WADA Prohibited List and peptides

FDA

US Food and Drug Administration

US regulator. Maintains the Category 1 Bulk Drug Substances list under section 503A. The FDA position on a research peptide is widely cited internationally, including by UK media.

Deep-dive coming soon

EMA

European Medicines Agency

EU centralised medicines authority. EMA opinions are not directly binding in the UK post-Brexit but are frequently mirrored by MHRA decisions on GLP-1 and peptide medicines.

Deep-dive coming soon

ASA

Advertising Standards Authority

UK advertising regulator. Enforces the CAP Code on health and weight-loss claims. POM medications cannot be advertised to the public.

ASA rules on weight-loss adverts

Live regulatory tracker

What UK regulators are saying about peptides and GLP-1 medicines

Last updated 2026-07-08

The data behind this hub

PeptideClear maintains these as refreshable datasets rather than one-off articles. Each carries its own source, methodology and last-updated date.

Live data tracker

UK GLP-1 prescribing tracker →

Monthly NHS England primary-care prescribing volumes for GLP-1 medications, rebuilt as each new month publishes. Dated chart, month-by-month table, full methodology.

Source: NHSBSA English Prescribing Dataset

Live data tracker

MHRA enforcement and safety tracker →

Every MHRA safety alert, enforcement action and drug safety update relevant to weight-loss medicines and peptides, dated and linked to the gov.uk original.

Source: gov.uk / MHRA

Check it yourself: the official sources

PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.

MHRA
MHRA Products portal
The Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
MHRA
Drug Safety Update
The MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
MHRA
Report a fake or illegally supplied medicine
The MHRA route for reporting a website or seller supplying medicines illegally, and for reporting a product you believe is counterfeit.
Advertising Standards Authority
CAP Code and ASA rulings
The UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
World Anti-Doping Agency
WADA Prohibited List
The annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
legislation.gov.uk
Human Medicines Regulations 2012
The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.

Per-compound UK legal status pages

Dedicated UK regulatory status pages for the most-searched peptides and GLP-1 medicines. Each one summarises the Misuse of Drugs Act position, the Psychoactive Substances Act position, the MHRA marketing authorisation position, the WADA Prohibited List position and the ASA advertising framing.

How we build this hub

We pull primary-source statements from MHRA, FDA, WADA, EMA and ASA directly. We do not paraphrase secondary reporting. Where a position has shifted, we date the entry and link to the regulator's own page so the reader can verify. Items still pending source confirmation are held back from the ticker until an editor verifies them against the regulator's own published record.

This page is editorial commentary. It is not legal advice. For binding interpretation of any regulator's position, consult the regulator directly or a qualified UK medicines lawyer.

Frequently asked questions

Who regulates peptides in the UK?

There is no single peptide regulator. MHRA regulates licensed medicines (including all GLP-1 weight-management medicines). The Office for Product Safety and Standards covers topical cosmetic peptides under the UK Cosmetics Regulation 2013. The Food Standards Agency covers ingestible collagen as a food supplement. Research peptides sold under "research use only" framing sit outside the medicines classification entirely.

Are research peptides like BPC-157 legal to buy in the UK?

BPC-157 and most other research peptides are not controlled drugs under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. UK retailers can sell them lawfully only when labelled "research use only, not for human or animal consumption" and when no therapeutic claim is made. The moment a seller makes a therapeutic claim, the product becomes an unlicensed medicinal product and MHRA can act.

Why can UK clinics not advertise Wegovy or Mounjaro by name?

All licensed GLP-1 weight-management medicines are Prescription Only Medicines (POM). The Human Medicines Regulations 2012 prohibit advertising POM to the public. UK clinics can describe themselves as offering weight management care or generic "GLP-1 medications" but cannot promote a specific branded medicine to consumers. ASA has upheld multiple rulings on this.

What does the WADA Prohibited List mean for a UK athlete?

UK Anti-Doping (UKAD) enforces the WADA Prohibited List on tested athletes under UKAD, British Olympic Association or international federation jurisdiction. Section S2 prohibits peptide hormones, growth factors and related substances at all times (in and out of competition). BPC-157 sits under S0. There is no detection-free or wash-out interval for these substances; metabolite detection windows extend well beyond any use period and any positive test is a violation.

How often do these regulators update their positions?

WADA publishes the Prohibited List annually, in force from 1 January each year. MHRA issues Drug Safety Updates and enforcement notices on a rolling basis. FDA reviews the Category 1 Bulk Drug Substances list approximately yearly. ASA rulings are published as cases close. The live tracker above pulls the most recent items we have surfaced.